// App-Quantinova.ai

4046 : Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

Researchers

Presenter

  • Toshihiko Doi

Principal Investigators

  • Sarina Anne Piha-Paul

  • Shadia Ibrahim Jalal

  • Hieu Mai-Dang

  • Sanatan Saraf

  • Minori Koshiji

  • Ildiko Csiki

  • Jaafar Bennouna

Medical Centers

  • National Cancer Center Hospital, Tokyo, Japan

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Indiana University School of Medicine, Indianapolis, IN

  • Merck & Co., Inc., Kenilworth, NJ

  • Merck & Co. Inc., Rahway, NJ

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

Locations

  • United States

  • France

  • Japan

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

  • Squamous cell carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02054806

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved